All AI, analytics and decision support articles – Page 3
-
NewsAI adoption in life science labs faces a growing skills barrier
Pistoia Alliance survey also found that the greatest benefit for lab digitalisation has shifted from efficiency to innovation.
-
NewsLilly to site next US manufacturing facility in Texas
The new $6.5 billion Houston site will manufacture active pharmaceutical ingredients (APIs) in support of the company’s pipeline of small molecule medicines.
-
NewsMerck looks to digital to close discovery and biomanufacturing workflow gaps
Extends its digital transformation partnership with Siemens to make greater use of automation, data and AI in its services.
-
ArticleMicrobiology/RMM In-Depth Focus 2025
This in-depth focus features articles on rapid microbiological methods, quality control, and using AI to read agar plates.
-
ArticleEuropean Pharmaceutical Review Issue 3 2025
EPR Issue 3 includes articles on microbiology, downstream processing, manufacturing, drug formulation and more.
-
NewsLilly picks Virginia for the first of its four new US manufacturing facilities
The new $5 billion manufacturing site is set to become the company’s first integrated facility for API and drug product manufacturing.
-
NewsGilead breaks ground on AI-enabled US manufacturing hub
Says the Bay Area building’s digital infrastructure will make it one of biopharma’s leading artificial intelligence-powered centres.
-
News
Amgen to build $600m science and innovation centre in the US
The new Thousand Oaks, California facility will incorporate advanced automation and digital capabilities.
-
WebinarThe future of contamination control in pharma: from compliance to innovation
This webinar explores the benefits of accelerated microbial identification using MALDI-TOF in pharmaceutical contamination control strategies.
-
News
Lilly to sell off Branchburg site as its US manufacturing plans take shape
The pharma company’s digital innovation efforts also progress with the opening of a new Hyderabad facility.
-
ArticleAI Act: data governance and compliance strategy implications in Pharma
In this article, Patrice Navarro, Tech Partner (Healthcare & Life Sciences Sector), Clifford Chance, discusses the AI Act and the related compliance considerations for pharmaceutical companies in the EU.
-
NewsSanofi accelerates towards its ‘factory of the future’ vision
New digital initiative will support the pharma company’s manufacturing and supply chain ambitions.
-
NewsTechnology advancement to drive lab automation market through next decade
While high costs are hindering growth in the lab automation market, research highlights that new innovations like AI offer potential to expand this rapidly evolving industry.
-
WebinarHarnessing AI to transform quality and manufacturing in life sciences
This webinar explores innovative, purpose-built AI solutions that elevate compliance and efficiency in quality and manufacturing operations.
-
ReportPharma Horizons: environmental monitoring
This exclusive report addresses the key obstacles and innovations shaping pharmaceutical environmental monitoring, from QC and contamination control, to the impact of advanced technologies and regulatory changes. Discover practical solutions you can implement to drive progress for your organisation.
-
WebinarAchieving rapid microbial method validation with precise reference standard quantification
This webinar explores validation of rapid microbial methods with ready-to-use reference materials, a new industry standard in microbial QC testing.
-
NewsCPI launches first-of-a-kind digitalisation framework
CPI’s strategy will help pharmaceutical industry partners to accelerate digitalisation of the pharmaceutical manufacturing process.
-
ArticleBeyond instruments: streamlining process technology implementation in biopharmaceutical manufacturing
Colleagues from biopharmaceutical company MSD reveal what it takes to fully realise the benefits of PAT implementation.
-
NewsPrioritise cultural change to enhance pharma digital innovation efforts, says Pistoia Alliance
The research highlights that major barriers to digital innovation in life sciences include cultural attitudes on AI’s potential, governance and digital skills.
-
OpinionAI in pharmaceutical development: hype or panacea?
Dave Elder reflects on the array of applications for AI to facilitate successful drug development, though proof remains elusive.